Insys Therapeutics (INSY) : During the past 4 weeks, traders have been relatively bearish on Insys Therapeutics (INSY), hence the stock is down -18.98% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.29% relative to the S&P 500. The 4-week change in the price of the stock is -19.41% and the stock has fallen -6.13% in the past 1 week.
The stock has recorded a 20-day Moving Average of 14.03% and the 50-Day Moving Average is 23.25%.The 200 Day SMA reached 30.6%
Insys Therapeutics (NASDAQ:INSY): The stock opened in the green at $11.92 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $12 and a low of $11.55 for the day. The stock did not find buyers even at the lows and closed at $11.79 recording a loss of -2.40%. 895,378 shares exchanged hands during the trading day. The stock had closed at $11.79 in the previous days trading.
Insys Therapeutics (INSY) : 3 investment research analysts covering Insys Therapeutics (INSY) have an average price target of $24 for the near short term. The highest target price given by the Brokerage Firm to the stock is $28 and the lowest target is $22 for the short term. Analysts expect the variance to be within $3.46 of the average price.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution, an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.